WO2009086416A1 - Therapeutic cancer treatments - Google Patents
Therapeutic cancer treatments Download PDFInfo
- Publication number
- WO2009086416A1 WO2009086416A1 PCT/US2008/088222 US2008088222W WO2009086416A1 WO 2009086416 A1 WO2009086416 A1 WO 2009086416A1 US 2008088222 W US2008088222 W US 2008088222W WO 2009086416 A1 WO2009086416 A1 WO 2009086416A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- hedgehog
- chemotherapeutic
- patient
- compound
- Prior art date
Links
- ZTSXELJZZFAVAR-ZHVAAGGLSA-N CCC12O[C@@](CC3)(CC(C)C(C4)[C@@H]3C(CC3)[C@H]4[C@@](C)(CC4)[C@H]3CC4=O)[C@H](C)[C@@H]1N(CC(N(C)C)=O)C[C@@H](C)C2 Chemical compound CCC12O[C@@](CC3)(CC(C)C(C4)[C@@H]3C(CC3)[C@H]4[C@@](C)(CC4)[C@H]3CC4=O)[C@H](C)[C@@H]1N(CC(N(C)C)=O)C[C@@H](C)C2 ZTSXELJZZFAVAR-ZHVAAGGLSA-N 0.000 description 1
- 0 C[C@@]1C(CC2)(CC(C)=C(C3)*2[C@@](CC2)[C@]3[C@@](C)(CC3)[C@@]2CC3=O)O[C@]2[C@]1N(CCNC(C(C)(C)C)=O)C[C@@](C)C2 Chemical compound C[C@@]1C(CC2)(CC(C)=C(C3)*2[C@@](CC2)[C@]3[C@@](C)(CC3)[C@@]2CC3=O)O[C@]2[C@]1N(CCNC(C(C)(C)C)=O)C[C@@](C)C2 0.000 description 1
- LDQURTUYILCCDN-VIPHERAESA-N C[C@H]1[C@](CC2)(CC(C)=C(C3)C2[C@H](CC2)[C@H]3[C@@](C)(CC3)[C@H]2C[C@H]3NC(C)=O)OC2[C@H]1NC[C@@H](C)C2 Chemical compound C[C@H]1[C@](CC2)(CC(C)=C(C3)C2[C@H](CC2)[C@H]3[C@@](C)(CC3)[C@H]2C[C@H]3NC(C)=O)OC2[C@H]1NC[C@@H](C)C2 LDQURTUYILCCDN-VIPHERAESA-N 0.000 description 1
- MQJMBVPAUCXBPE-FENRTGCLSA-N C[C@H]1[C@](CC2)(CC(C)=C(C3)[C@@H]2C(CC2)[C@H]3[C@@](C)(CC3)[C@H]2C[C@H]3N(/C=C\[NH2+2])N)OC2[C@H]1NC[C@@H](C)C2 Chemical compound C[C@H]1[C@](CC2)(CC(C)=C(C3)[C@@H]2C(CC2)[C@H]3[C@@](C)(CC3)[C@H]2C[C@H]3N(/C=C\[NH2+2])N)OC2[C@H]1NC[C@@H](C)C2 MQJMBVPAUCXBPE-FENRTGCLSA-N 0.000 description 1
- KGBSFBGGUYBTIP-QMBHTTJASA-N C[C@H]1[C@](CC2)(CC(C)=C(C3)[C@@H]2[C@H](CC2)C3[C@@](C)(CC3)[C@H]2CC3=O)O[C@](C)(C[C@H](C)C2)C1N2S(C)(=O)=O Chemical compound C[C@H]1[C@](CC2)(CC(C)=C(C3)[C@@H]2[C@H](CC2)C3[C@@](C)(CC3)[C@H]2CC3=O)O[C@](C)(C[C@H](C)C2)C1N2S(C)(=O)=O KGBSFBGGUYBTIP-QMBHTTJASA-N 0.000 description 1
- PDPNIPZUTUOGPN-MEJQXHAYSA-N C[C@H]1[C@](CC2)(CC(C)=C(C3)[C@@H]2[C@H](CC2)[C@H]3C(C)(CC3)C2CC3=O)OC(C[C@H](C)C2)[C@H]1N2C(C)=O Chemical compound C[C@H]1[C@](CC2)(CC(C)=C(C3)[C@@H]2[C@H](CC2)[C@H]3C(C)(CC3)C2CC3=O)OC(C[C@H](C)C2)[C@H]1N2C(C)=O PDPNIPZUTUOGPN-MEJQXHAYSA-N 0.000 description 1
- HZLFFNCLTRVYJG-GDNISXJWSA-N C[C@H]1[C@](CC2)(CC(C)=C(C3)[C@@H]2[C@H](CC2)[C@H]3[C@@](C)(CC3)[C@H]2C[C@H]3NS(C)(=O)=O)OC2[C@H]1NC[C@@H](C)C2 Chemical compound C[C@H]1[C@](CC2)(CC(C)=C(C3)[C@@H]2[C@H](CC2)[C@H]3[C@@](C)(CC3)[C@H]2C[C@H]3NS(C)(=O)=O)OC2[C@H]1NC[C@@H](C)C2 HZLFFNCLTRVYJG-GDNISXJWSA-N 0.000 description 1
- WUTVGYIYHVQBAK-ZDDWXUEWSA-N C[C@H]1[C@](CC2)(CC(C)=C(C3)[C@@H]2[C@H]2[C@H]3[C@@](C)(CCCC3)C3CC2)OC2[C@H]1NC[C@@H](C)C2 Chemical compound C[C@H]1[C@](CC2)(CC(C)=C(C3)[C@@H]2[C@H]2[C@H]3[C@@](C)(CCCC3)C3CC2)OC2[C@H]1NC[C@@H](C)C2 WUTVGYIYHVQBAK-ZDDWXUEWSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2010006991A MX2010006991A (en) | 2007-12-27 | 2008-12-23 | Therapeutic cancer treatments. |
BRPI0821779A BRPI0821779A2 (en) | 2007-12-27 | 2008-12-23 | therapeutic treatment of cancer |
JP2010540875A JP2011522773A (en) | 2007-12-27 | 2008-12-23 | Methods of treating cancer with therapeutic agents |
CA2710377A CA2710377A1 (en) | 2007-12-27 | 2008-12-23 | Therapeutic cancer treatments |
CN2008801239807A CN101918420A (en) | 2007-12-27 | 2008-12-23 | Therapeutic cancer treatments |
EP08868388A EP2225254A4 (en) | 2007-12-27 | 2008-12-23 | Therapeutic cancer treatments |
AU2008345151A AU2008345151A1 (en) | 2007-12-27 | 2008-12-23 | Therapeutic cancer treatments |
ZA2010/04403A ZA201004403B (en) | 2007-12-27 | 2010-06-22 | Therapeutic cancer treatments |
IL206632A IL206632A0 (en) | 2007-12-27 | 2010-06-27 | Compositions comprising a hedgehog inhibitor for use in extending cancer survival |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1716007P | 2007-12-27 | 2007-12-27 | |
US11/965,688 | 2007-12-27 | ||
US11/965,688 US7812164B2 (en) | 2006-12-28 | 2007-12-27 | Cyclopamine analogs |
US61/017,160 | 2007-12-27 | ||
US11896908P | 2008-12-01 | 2008-12-01 | |
US61/118,969 | 2008-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009086416A1 true WO2009086416A1 (en) | 2009-07-09 |
Family
ID=40824720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/088222 WO2009086416A1 (en) | 2007-12-27 | 2008-12-23 | Therapeutic cancer treatments |
Country Status (16)
Country | Link |
---|---|
US (1) | US20090181997A1 (en) |
EP (1) | EP2225254A4 (en) |
JP (1) | JP2011522773A (en) |
KR (1) | KR20100137416A (en) |
CN (1) | CN101918420A (en) |
AR (1) | AR070047A1 (en) |
AU (1) | AU2008345151A1 (en) |
BR (1) | BRPI0821779A2 (en) |
CA (1) | CA2710377A1 (en) |
CL (1) | CL2008003901A1 (en) |
IL (1) | IL206632A0 (en) |
MX (1) | MX2010006991A (en) |
PE (1) | PE20091180A1 (en) |
TW (1) | TW200934784A (en) |
WO (1) | WO2009086416A1 (en) |
ZA (1) | ZA201004403B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011025838A1 (en) | 2009-08-25 | 2011-03-03 | Abraxis Bioscience, Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
EP2389068A1 (en) * | 2009-01-23 | 2011-11-30 | Cancer Research Technology Limited | Hedgehog pathway inhibitors |
US8895576B2 (en) | 2006-12-28 | 2014-11-25 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US9238672B2 (en) | 2007-12-27 | 2016-01-19 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
US9879293B2 (en) | 2009-08-05 | 2018-01-30 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
US10369147B2 (en) | 2015-06-04 | 2019-08-06 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
US20110183948A1 (en) * | 2010-01-15 | 2011-07-28 | Infinity Pharmaceuticals, Inc. | Treatment of fibrotic conditions using hedgehog inhibitors |
WO2012006589A2 (en) * | 2010-07-08 | 2012-01-12 | Infinity Pharmaceuticals, Inc. | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling |
US20120010229A1 (en) * | 2010-07-08 | 2012-01-12 | Macdougall John R | Therapeutic regimens for hedgehog-associated cancers |
RU2492855C2 (en) * | 2011-02-15 | 2013-09-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии" СО РАМН (ФГБУ "НИИ онкологии" СО РАМН) | Method for combination therapy of stage ii and iii non-small cell lung cancer with pre- and postoperative chemotherapy |
CA2752008A1 (en) | 2011-09-13 | 2013-03-13 | Universite De Montreal | Combination therapy using ribavirin as elf4e inhibitor |
EP3169312B1 (en) * | 2014-07-17 | 2020-09-02 | BioCurity Pharmaceuticals Inc. | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent |
JP6815331B2 (en) * | 2015-04-21 | 2021-01-20 | ジェネンテック, インコーポレイテッド | Compositions and Methods for Prostate Cancer Analysis |
CN107137406B (en) * | 2016-03-01 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | Application of Hedgehog signal pathway inhibitor in preparation of medicine for treating EGFR (epidermal growth factor receptor) over-expression cancer |
KR102469406B1 (en) * | 2016-08-10 | 2022-11-21 | 셀젠 콴티셀 리서치, 인크. | Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphoma |
CN110494452B (en) | 2017-04-03 | 2023-08-25 | 豪夫迈·罗氏有限公司 | Antibodies that bind STEAP-1 |
KR20210003731A (en) | 2018-07-31 | 2021-01-12 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | Combination products of Bcl-2 inhibitor and MDM2 inhibitor and their use in the prevention and/or treatment of diseases |
AU2019314819A1 (en) | 2018-07-31 | 2020-10-22 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
CN110772521A (en) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2 inhibitor or Bcl-2/Bcl-xL inhibitor and BTK inhibitor combination product and application thereof |
UA125241C2 (en) | 2018-07-31 | 2022-02-02 | Есентейдж Фарма (Сучжоу) Ко., Лтд. | Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/orbendamustine or bcl-2 inhibitor combined with chop |
CN115282133A (en) * | 2021-12-06 | 2022-11-04 | 温州医科大学 | Application of hypocrellin B in preparation of anti-colon cancer drugs |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005013800A2 (en) * | 2003-07-15 | 2005-02-17 | The Johns Hopkins University | Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity |
WO2007053596A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20070191410A1 (en) * | 2004-08-27 | 2007-08-16 | Julian Adams | Cyclopamine analogues and methods of use thereof |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US7741298B2 (en) * | 1997-06-20 | 2010-06-22 | New York University | Method and compositions for inhibiting tumorigenesis |
US6238876B1 (en) * | 1997-06-20 | 2001-05-29 | New York University | Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma |
US7709454B2 (en) * | 1997-06-20 | 2010-05-04 | New York University | Methods and compositions for inhibiting tumorigenesis |
US7291626B1 (en) * | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
US6867216B1 (en) * | 1998-04-09 | 2005-03-15 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signal pathways, compositions and uses related thereto |
US6432970B2 (en) * | 1998-04-09 | 2002-08-13 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
CA2339330A1 (en) * | 1998-08-13 | 2000-02-24 | University Of Southern California | Methods to increase blood flow to ischemic tissue |
US6291516B1 (en) * | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
US20070021493A1 (en) * | 1999-09-16 | 2007-01-25 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
ATE328002T1 (en) * | 1999-10-13 | 2006-06-15 | Univ Johns Hopkins Med | COMPOUNDS FOR REGULATING THE HEDGEHOG SIGNALING PATH, COMPOSITIONS AND USES THEREOF |
US6552016B1 (en) * | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
US6893637B1 (en) * | 1999-10-21 | 2005-05-17 | Zymogenetics, Inc. | Method of treating fibrosis |
IL133809A0 (en) * | 1999-12-30 | 2001-04-30 | Yeda Res & Dev | Steroidal alkaloids and pharmaceutical compositions comprising them |
US6613798B1 (en) * | 2000-03-30 | 2003-09-02 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
US7708998B2 (en) * | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
AU2002247847A1 (en) * | 2001-04-09 | 2002-10-21 | Lorantis Limited | Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
AUPR602401A0 (en) * | 2001-06-29 | 2001-07-26 | Smart Drug Systems Inc | Sustained release delivery system |
CA2452152A1 (en) * | 2001-07-02 | 2002-10-10 | Sinan Tas | Use of cyclopamine in the treatment of psoriasis |
JP2003192919A (en) * | 2001-10-17 | 2003-07-09 | Asahi Denka Kogyo Kk | Flame-retardant synthetic resin composition |
GB0221539D0 (en) * | 2002-09-17 | 2002-10-23 | Medical Res Council | Methods of treatment |
FR2850022B1 (en) * | 2003-01-22 | 2006-09-08 | Centre Nat Rech Scient | NOVEL USE OF MIFEPRISTONE AND ITS DERIVATIVES AS MODULATORS OF THE HEDGEHOG PROTEIN SIGNALING PATH AND ITS APPLICATIONS |
US20080095761A1 (en) * | 2003-10-01 | 2008-04-24 | The Johns Hopkins University | Hedgehog Signaling in Prostate Regeneration Neoplasia and Metastasis |
US20070231828A1 (en) * | 2003-10-01 | 2007-10-04 | Johns Hopkins University | Methods of predicting behavior of cancers |
US20080057071A1 (en) * | 2003-10-20 | 2008-03-06 | Watkins David N | Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer |
US20070281040A1 (en) * | 2004-09-30 | 2007-12-06 | The University Of Chicago | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents |
US20060252073A1 (en) * | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
WO2006124700A2 (en) * | 2005-05-12 | 2006-11-23 | Introgen Therapeutics, Inc. | P53 vaccines for the treatment of cancers |
WO2007056135A1 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Method of treating cancers with saha and pemetrexed |
WO2007076294A2 (en) * | 2005-12-15 | 2007-07-05 | Wei Chen | Method of screening the activity of the smoothened receptor to identify theraputic modulation agents or diagnose disease |
EP1978973B1 (en) * | 2005-12-27 | 2011-11-16 | Genentech, Inc. | Use hedgehog kinase antagonists to inhibit hedgehog signaling and to treat cancer |
WO2008121102A2 (en) * | 2006-02-21 | 2008-10-09 | The Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
WO2007123511A2 (en) * | 2006-03-24 | 2007-11-01 | Infinity Pharmaceuticals, Inc. | Dosing regimens for the treatment of cancer |
WO2008070357A2 (en) * | 2006-10-31 | 2008-06-12 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Smoothened polypeptides and methods of use |
US20080182859A1 (en) * | 2006-11-02 | 2008-07-31 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
TWI433674B (en) * | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | Cyclopamine analogs |
CA2679845A1 (en) * | 2007-03-07 | 2008-09-12 | Infinity Discovery, Inc. | Cyclopamine lactam analogs and methods of use thereof |
NZ579361A (en) * | 2007-03-07 | 2012-04-27 | Infinity Discovery Inc | Heterocyclic cyclopamine analogs and methods of use thereof |
CN101663033B (en) * | 2007-04-18 | 2013-01-16 | 默沙东公司 | Triazole derivatives which are SMO antagonists |
WO2009049258A1 (en) * | 2007-10-12 | 2009-04-16 | The Johns Hopkins University | Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies |
BRPI0820856A2 (en) * | 2007-12-13 | 2019-05-14 | Siena Bhiotech.S.P.A. | of the hedgehog reaction series and their therapeutic applications |
US20100222287A1 (en) * | 2007-12-27 | 2010-09-02 | Mcgovern Karen J | Therapeutic Cancer Treatments |
US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
AU2008345097A1 (en) * | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
CL2009001479A1 (en) * | 2008-07-02 | 2010-01-04 | Infinity Pharmaceuticals Inc | A method of isolating a deglycosylated veratrum alkaloid comprising providing a veratrum plant material, contacting an aqueous solution, and extracting the veratrum plant material with a solvent to provide an extract comprising said alkaloid. |
US20110183948A1 (en) * | 2010-01-15 | 2011-07-28 | Infinity Pharmaceuticals, Inc. | Treatment of fibrotic conditions using hedgehog inhibitors |
US20120010229A1 (en) * | 2010-07-08 | 2012-01-12 | Macdougall John R | Therapeutic regimens for hedgehog-associated cancers |
WO2012006589A2 (en) * | 2010-07-08 | 2012-01-12 | Infinity Pharmaceuticals, Inc. | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling |
-
2008
- 2008-12-23 AU AU2008345151A patent/AU2008345151A1/en not_active Abandoned
- 2008-12-23 CN CN2008801239807A patent/CN101918420A/en active Pending
- 2008-12-23 MX MX2010006991A patent/MX2010006991A/en not_active Application Discontinuation
- 2008-12-23 KR KR1020107016717A patent/KR20100137416A/en not_active Application Discontinuation
- 2008-12-23 JP JP2010540875A patent/JP2011522773A/en active Pending
- 2008-12-23 CA CA2710377A patent/CA2710377A1/en not_active Abandoned
- 2008-12-23 US US12/343,245 patent/US20090181997A1/en not_active Abandoned
- 2008-12-23 AR ARP080105739A patent/AR070047A1/en not_active Application Discontinuation
- 2008-12-23 PE PE2008002178A patent/PE20091180A1/en not_active Application Discontinuation
- 2008-12-23 WO PCT/US2008/088222 patent/WO2009086416A1/en active Application Filing
- 2008-12-23 BR BRPI0821779A patent/BRPI0821779A2/en not_active IP Right Cessation
- 2008-12-23 EP EP08868388A patent/EP2225254A4/en not_active Withdrawn
- 2008-12-24 CL CL2008003901A patent/CL2008003901A1/en unknown
- 2008-12-26 TW TW097151085A patent/TW200934784A/en unknown
-
2010
- 2010-06-22 ZA ZA2010/04403A patent/ZA201004403B/en unknown
- 2010-06-27 IL IL206632A patent/IL206632A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005013800A2 (en) * | 2003-07-15 | 2005-02-17 | The Johns Hopkins University | Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity |
US20070191410A1 (en) * | 2004-08-27 | 2007-08-16 | Julian Adams | Cyclopamine analogues and methods of use thereof |
WO2007053596A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
Non-Patent Citations (2)
Title |
---|
See also references of EP2225254A4 * |
SHAFAEE ET AL.: "Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells.", CANCER CHEMOTHER PHARMACOL., vol. 58, no. 6, 2006, pages 765 - 770 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9669011B2 (en) | 2006-12-28 | 2017-06-06 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US11602527B2 (en) | 2006-12-28 | 2023-03-14 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US11007181B2 (en) | 2006-12-28 | 2021-05-18 | Infinity Pharmaceuticals, Inc. | Cyclopamine analogs |
US10821102B2 (en) | 2006-12-28 | 2020-11-03 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US8895576B2 (en) | 2006-12-28 | 2014-11-25 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US9145422B2 (en) | 2006-12-28 | 2015-09-29 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US10406139B2 (en) | 2006-12-28 | 2019-09-10 | Infinity Pharmaceuticals, Inc. | Cyclopamine analogs |
US10314827B2 (en) | 2006-12-28 | 2019-06-11 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US10045970B2 (en) | 2006-12-28 | 2018-08-14 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US9951083B2 (en) | 2006-12-28 | 2018-04-24 | Infinity Pharmaceuticals, Inc. | Cyclopamine analogs |
US9492435B2 (en) | 2006-12-28 | 2016-11-15 | Infinity Pharmaceuticals, Inc. | Cyclopamine analogs |
US9238672B2 (en) | 2007-12-27 | 2016-01-19 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
EP2389068A4 (en) * | 2009-01-23 | 2012-07-18 | Cancer Rec Tech Ltd | Hedgehog pathway inhibitors |
EP2389068A1 (en) * | 2009-01-23 | 2011-11-30 | Cancer Research Technology Limited | Hedgehog pathway inhibitors |
US9879293B2 (en) | 2009-08-05 | 2018-01-30 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
JP2013503174A (en) * | 2009-08-25 | 2013-01-31 | アブラクシス バイオサイエンス, エルエルシー | Combination therapy using nanoparticle compositions of taxanes and hedgehog inhibitors |
WO2011025838A1 (en) | 2009-08-25 | 2011-03-03 | Abraxis Bioscience, Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
US9879025B2 (en) | 2010-09-14 | 2018-01-30 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
US9394313B2 (en) | 2010-09-14 | 2016-07-19 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
US10369147B2 (en) | 2015-06-04 | 2019-08-06 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
US10695344B2 (en) | 2015-06-04 | 2020-06-30 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
US11413283B2 (en) | 2015-06-04 | 2022-08-16 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
Also Published As
Publication number | Publication date |
---|---|
US20090181997A1 (en) | 2009-07-16 |
TW200934784A (en) | 2009-08-16 |
ZA201004403B (en) | 2012-02-29 |
EP2225254A1 (en) | 2010-09-08 |
KR20100137416A (en) | 2010-12-30 |
EP2225254A4 (en) | 2011-03-30 |
CN101918420A (en) | 2010-12-15 |
AU2008345151A1 (en) | 2009-07-09 |
CL2008003901A1 (en) | 2009-07-24 |
JP2011522773A (en) | 2011-08-04 |
PE20091180A1 (en) | 2009-08-26 |
MX2010006991A (en) | 2010-09-30 |
AR070047A1 (en) | 2010-03-10 |
CA2710377A1 (en) | 2009-07-09 |
BRPI0821779A2 (en) | 2019-09-24 |
IL206632A0 (en) | 2010-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009086416A1 (en) | Therapeutic cancer treatments | |
US20100297118A1 (en) | Therapeutic Cancer Treatments | |
US20100222287A1 (en) | Therapeutic Cancer Treatments | |
US9457019B2 (en) | Methods for inhibiting tie-2 kinase useful in the treatment of cancer | |
AU2013404949B2 (en) | Methods for inhibiting TIE2 kinase useful in the treatment of cancer | |
AU2019240572B2 (en) | Compositions and methods for treating cancers associated with ETBR activation | |
WO2012006584A2 (en) | Therapeutic regimens for hedgehog-associated cancers | |
KR20200026969A (en) | Compositions for Parenteral Administration of Therapeutic Agents | |
KR20140040728A (en) | Methods of treating mesothelioma with a pi3k inhibitor compound | |
EP3057593B1 (en) | Treatment for pancreatic cancer | |
US20170071905A1 (en) | Compositions and methods for drug-sensitization or inhibition of a cancer cell | |
CN113939297A (en) | Bifluoroalkyl-1, 4-benzodiazepinone compounds for the treatment of Notch activated breast cancer | |
TW201722422A (en) | Rational combination therapy for the treatment of cancer | |
US20230277522A9 (en) | Methods for treating vascular malformations | |
WO2021050917A1 (en) | Phospholipid ether conjugates as cancer-targeting drug vehicles | |
JP6945587B2 (en) | Methods of Inhibiting TIE2 Kinase Useful for Cancer Treatment | |
WO2023158514A1 (en) | Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization | |
EP4013417A1 (en) | Methods and compositions for treating vascular malformations | |
JP2018524292A (en) | Administration of aurora kinase inhibitors and chemotherapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880123980.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08868388 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2710377 Country of ref document: CA Ref document number: MX/A/2010/006991 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2304/KOLNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008345151 Country of ref document: AU Ref document number: 586429 Country of ref document: NZ Ref document number: 2010540875 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008868388 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008345151 Country of ref document: AU Date of ref document: 20081223 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20107016717 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010131172 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0821779 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100629 |